Skip to main content
. 2021 May;18(5):788–798. doi: 10.1513/AnnalsATS.202002-096OC

Figure 2.

Figure 2.

Severe exacerbation and investigator-reported pneumonia resulting in hospitalization/prolonged hospitalization or death: (A) Kaplan-Meier plot of time-to-first event and (B) cumulative plot. (A) Patients experiencing a severe exacerbation up to Week 52: FF/UMEC/VI, n = 447 (11%); FF/VI, n = 461 (11%); UMEC/VI, n = 272 (13%). Patients with investigator-reported pneumonia resulting in hospitalization/prolonged hospitalization or death up to Week 52: FF/UMEC/VI, n = 199 (5%); FF/VI, n = 170 (4%); UMEC/VI, n = 57 (3%). FF = fluticasone furoate; UMEC = umeclidinium; VI = vilanterol.